Damdamon, Bajari D.
HRN: 23-66-01 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/01/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
12/01/2024
12/08/2024
IV
50mg
Q12hours
PCAP-C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes